{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:59:39Z","timestamp":1774997979453,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA142665"],"award-info":[{"award-number":["CA142665"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["GM115279"],"award-info":[{"award-number":["GM115279"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA21765"],"award-info":[{"award-number":["CA21765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0216328","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T18:13:35Z","timestamp":1557166415000},"page":"e0216328","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-8180","authenticated-orcid":true,"given":"Seth E.","family":"Karol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Janke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura B.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique A.","family":"Payton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"CH Pui","year":"2013","journal-title":"Semin Hematol"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.","volume":"14","author":"A Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/leu.2009.251","article-title":"Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia","volume":"24","author":"K Schmiegelow","year":"2010","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"ref4","first-page":"S62","article-title":"Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000","volume":"225","author":"M Schrappe","year":"2013","journal-title":"Klinische Padiatrie"},{"issue":"26","key":"ref5","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"CH Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"N Boissel","year":"2018","journal-title":"Blood"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"C Liu","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2011-09-381731","article-title":"Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia","volume":"119","author":"JD Kawedia","year":"2012","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e27300","DOI":"10.1002\/pbc.27300","article-title":"Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia","author":"SS Mogensen","year":"2018","journal-title":"Pediatric blood & cancer"},{"issue":"15","key":"ref10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2015-05-643601","article-title":"Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia","volume":"126","author":"SE Karol","year":"2015","journal-title":"Blood"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia","volume":"117","author":"JD Kawedia","year":"2011","journal-title":"Blood"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2405032","article-title":"High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis","volume":"22","author":"B Patel","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1470-2045(12)70274-7","article-title":"Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial","volume":"13","author":"LA Mattano Jr.","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref14","article-title":"Effects of dexamethasone (DEX) vs prednisone (PDN) and high-dose methotrexate (HD-MTX) vs Capizzi methotrexate\/asparaginase (C-MTX\/ASNase) on osteonecrosis (ON) incidence in children and young adults with high risk acute lymphoblastic leukemia (HR ALL): a report from the Children\u2019s Oncology Group (COG) Study AALL0232","author":"LAJ Mattano","year":"2012","journal-title":"Blood"},{"issue":"15","key":"ref15","article-title":"Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Children&apos;s Oncology Group (COG) study AALL0331","volume":"31","author":"LA Mattano","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"e0135134","DOI":"10.1371\/journal.pone.0135134","article-title":"Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.","volume":"10","author":"LB Ramsey","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"e0151433","DOI":"10.1371\/journal.pone.0151433","article-title":"Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model","volume":"11","author":"C Liu","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jor.20733","article-title":"A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday","volume":"27","author":"L Yang","year":"2009","journal-title":"J Orthop Res"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajpath.2013.03.004","article-title":"Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis","volume":"183","author":"LJ Janke","year":"2013","journal-title":"Am J Pathol"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa033513","article-title":"Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment","volume":"351","author":"A Holleman","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3283","article-title":"NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells","volume":"47","author":"SW Paugh","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"ref22","first-page":"331","article-title":"The Search for Synergy\u2014a Critical-Review from a Response-Surface Perspective","volume":"47","author":"WR Greco","year":"1995","journal-title":"Pharmacol Rev"},{"issue":"7","key":"ref23","first-page":"478","article-title":"High-throughput asparaginase activity assay in serum of children with leukemia","volume":"6","author":"CA Fernandez","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"ref24","article-title":"R: A language and environment for statistical computing","author":"RDC Team","year":"2006"},{"issue":"6","key":"ref25","first-page":"466","article-title":"Substrain-specific differences in survival and osteonecrosis incidence in a mouse model","volume":"62","author":"JD Kawedia","year":"2012","journal-title":"Comp Med"},{"issue":"20","key":"ref26","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children&apos;s Oncology Group Study AALL0232","volume":"34","author":"EC Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia","volume":"32","author":"N Toft","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"ref28","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"A Moricke","year":"2016","journal-title":"Blood"},{"issue":"13","key":"ref29","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"WH Tong","year":"2014","journal-title":"Blood"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26686","article-title":"Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation","volume":"64","author":"L Tram Henriksen","year":"2017","journal-title":"Pediatric blood & cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0216328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T17:04:14Z","timestamp":1589043854000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0216328"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0216328","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]}}}